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a novel mode of regulation of an SH2
domain that affects both the biochemical
properties of the SH2 domain and the bio-
logical effects of the molecule in which
it resides. It remains to be determined
whether other SH2 domains are regulated
in a similar manner. The ligand-specificity
of this mode of regulation is intriguing,
given that Src, Cas, and FAK, whose
association with tensin-3 is tyrosine
phosphorylation dependent, are all pro-
oncogenic, whereas the association of
tensin-3 with DLC1, a tumor suppressor,
is not affected by tyrosine phosphoryla-
tion. Thus the biological complexity of
tensin-3 function—oncogenic in some
contexts, antioncogenic in others—may
reflect not only the complexity of the
targets to which it binds but also the
complexity of its regulation.
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The protein kinase AKT is frequently activated in human cancers and has been implicated in resistance to
chemotherapy. In this issue of Cancer Cell, Pei et al. show that FKBP51 negatively regulates AKT through
the phosphatase PHLPP. This regulation appears to be a determinant of chemosensitivity in cancer cells.Despite increased interest in targeted
therapeutics, cytotoxic chemicals remain
the front-line defense against malignant
tumors. However, malignant tumors vary
greatly in their response to chemothera-
peutic agents. A compound might elicit
a strong apoptotic response in one tumor
but have little to no effect on another.
Furthermore, tumors initially sensitive to
treatment can develop resistance to
specific classes of agents or, in some
instances, develop a more generalized
chemoresistance to a large variety of
agents with distinct modes of action.
Therefore, there has been much interest
in defining molecular mechanisms un-
derlying this differential response and
identifying markers to predict response.
A hallmark of cellular transformation is
evasion from apoptotic stimuli, and
oncogenic pathways promoting aberrant
cell survival can also affect the general178 Cancer Cell 16, September 8, 2009 ª20response of a tumor cell to chemothera-
peutics.
AKT (also known as PKB) is a critical
survival kinase that is normally activated
in a growth-factor-dependent manner but
is constitutively activated at a high
frequency in tumors through oncogenic
events affecting its upstream regulation
(Engelman et al., 2006). The most impor-
tant upstream activators of AKT are the
class I phosphoinositide 3-kinases (PI3K),
which generate the lipid second mes-
sengerphosphatidylinositol-3,4,5-trisphos-
phate (PIP3). PI3K lipid products bind
directly to the pleckstrin homology (PH)
domain of AKT, thereby recruiting AKT to
the plasma membrane where it is subse-
quently activated (see below). Therefore,
the activation status of PI3K and the
levels of its lipid products are the key
factors dictating the level of AKT activity
in a cell. PTEN is a lipid phosphatase that09 Elsevier Inc.removes the critical 3-phosphate from
PIP3, thereby reversing PI3K signaling
and blocking AKT activation. Importantly,
PTEN is encoded by a tumor-suppressor
gene that is frequently mutated in human
cancers, and thesemutations are the likely
cause of aberrant AKT activation in many
tumors. Activating mutations and amplifi-
cations affecting the gene encoding the
p110a isoform of PI3K (PIK3CA) are also
common in cancers. Furthermore, other
common oncogene products, such as
Ras, receptor tyrosine kinases (e.g.,
EGFR, HER2, c-Met), and fusion proteins
(e.g., BCR-Abl), are all potent activators of
PI3K that lead to increasedAKT activation.
The large number of oncogenes and tumor
suppressors upstream of AKT results in
aberrantlyelevated levelsofAKTactivation
in the majority of sporadic cancers.
Full activation of AKT requires phos-
phorylation on two highly conserved
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vation loop of the kinase
domain and S473 in a hydro-
phobic motif just C-terminal
to the kinase domain. In
response to PI3K lipid prod-
ucts, T308 is phosphorylated
by PDK1, which also has
a PH domain directing PIP3
binding, whereas S473 is
primarily phosphorylated by
themammalian target of rapa-
mycin (mTOR) as a part of
mTOR complex 2 (mTORC2)
(Guertin and Sabatini, 2007;
Moraet al., 2004). Phosphory-
lation on T308 is essential for
AKT kinase activity, whereas
S473 phosphorylation is not.
However, S473 phosphoryla-
tion greatly increases AKT
activity and plays a key role
in stabilizing the activation
state of AKT and the sus-
tained phosphorylation of
T308 (Yang et al., 2002).
Therefore, the phosphoryla-
tion status of S473 is likely
to dictate the strength and
duration of AKT signaling
within a given cell. The
dephosphorylation of S473
appears to be primarily medi-
ated by two closely related
phosphatases, PHLPP1 and PHLPP2
(Brognard et al., 2007).
Through its control over a variety of
downstream substrates, AKT has the
capacity to drive tumor cell growth, prolif-
eration, metabolism, and survival (Man-
ning and Cantley, 2007). The role of AKT
in promoting cell survival through its inhibi-
tion of proapoptotic proteins and path-
ways suggests that the activation state of
AKT can affect the sensitivity of a given
tumor cell to chemotherapy. There have
been a number of studies demonstrating
a correlation between chemoresistance
and the levels of phosphorylated AKT
in tumors, and activated AKT can drive
resistance to commonchemotherapeutics
in cell and mouse tumor models (e.g., Kim
et al., 2005;Wendel et al., 2004). However,
specific factors within established tumors
that modulate both the threshold of AKT
activation and the subsequent response
to chemotherapy are poorly described.
In this issue of Cancer Cell, Pei and
colleagues identify the immunophilin
FKBP51 (also referred to as FKBP5) as
a link between AKT regulation and sensi-
tivity to chemotherapeutic compounds
(Pei et al., 2009). In a previous study,
FKBP51 expression levels were found
to correlate strongly with the sensitivity
of tumor cells to the cytidine analogs
gemcitabine and AraC (Li et al., 2008).
The current study extends these findings
to other classes of chemotherapeutics
and demonstrates that reduced levels
of FKBP51 render cells more resistant
to these drugs (Pei et al., 2009). In deter-
mining the mechanism, FKBP51 protein
levels were found to inversely correlate
with the levels of AKT activation in the
cells. Surprisingly, increasedor decreased
expression of FKBP51 leads to a corre-
sponding decrease or increase in S473
phosphorylation and AKT signaling to
downstream targets without substantially
affecting T308 phosphorylation. This
rather unique effect on AKT activation
demonstrated that the mechanism of
control by FKBP51 was unlikely to be
through effects on PI3K or
PIP3 levels but rather on
the kinases or phosphatases
controlling the phosphoryla-
tion status of S473. Indeed,
the ability of FKBP51 overex-
pression to both decrease
AKT-S473 phosphorylation
and enhance sensitivity to
gemcitabine was found to be
dependent on the AKT-S473
phosphatase PHLPP. Inter-
estingly, FKBP51 associates
with AKT through its con-
served FKBP domains and
with PHLPP through a C-ter-
minal TPR domain. The pepti-
dylprolyl isomerase activity of
FKBP51 is not required for
theeffectsonAKTphosphory-
lation, and FKBP51 does not
appear to affect PHLPP acti-
vity per se. The data suggest
that FKBP51 acts a scaffold
to facilitate the PHLPP-medi-
ated dephosphorylation of
AKT-S473 (Figure 1).
This study introduces an
interesting new component
contributing to the complex
molecularmechanismsaffect-
ing AKT activation. However,
many questions remain to be
addressed by future studies.
How are FKBP51 protein levels regulated
and are there regulatory inputs affect-
ing the putative scaffolding activity of
FKBP51? It is unclear from the current
study whether a steady-state complex of
FKBP51, PHLPP, and AKT exists within
cells or the complex is transient and
turning over rapidly. Is FKBP51 a tumor
suppressor? Evidence is provided that
FKBP51 levels are reduced in some
tumors and tumor-derived cell lines, and
such a reduction might contribute to
increased AKT-S473 phosphorylation
(Pei et al., 2009). However, oncogenic
events upstream of AKT result in an
increase in the levels ofPI3K lipidproducts
leading to AKT activation in a growth-
factor-independent manner, which is
probably an essential element in the trans-
forming properties of these genetic alter-
ations. Although it was not addressed in
the current study, it seems unlikely that
loss of FKBP51 alone would trigger AKT
activation in the absence of upstream
inputs. A variety of factors, such as the
Figure 1. Model of Regulatory Mechanisms Affecting AKT
Phosphorylation and Activation and the Consequences for
Chemosensitivity
The major event in AKT activation is its recruitment to the plasma membrane
via direct binding to PIP3. PIP3 levels are increased by PI3K activity and
decreased by PTEN activity. PI3K is activated by growth factor signaling
through both Ras and receptor tyrosine kinases (RTK), either directly or
through scaffolding adaptors. In response to PIP3 binding, AKT becomes fully
activated following phosphorylation on two major conserved residues. The
kinase PDK1, which must also bind to PIP3 in its regulation of AKT, phosphor-
ylates T308 on the activation loop of AKT. Phosphorylation of S473 within
a hydrophobic regulatory motif on AKT is mediated primarily by mTOR
complex 2 (mTORC2), but other kinases such as DNA-PK or AKT itself can
phosphorylate this residue under some conditions. AKT-S473 is dephos-
phorylated by the PHLLP phosphatase, and this is facilitated by the binding
of both AKT and PHLLP to FKBP51. Through effects on AKT phosphorylation
and activation, the cellular levels of FKBP51 affect the sensitivity to chemo-
therapeutics. High levels of FKBP51 lead to reduced AKT activity and
increased chemosensitivity, whereas low levels of FKBP51 lead to increased
AKT activity and chemoresistance.Cancer Cell 16, September 8, 2009 ª2009 Elsevier Inc. 179
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Previewsexistence and strength of negative feed-
back mechanisms, set the threshold of
AKT activation in a given setting. The
cellular levels of FKBP51 appear to be
another major factor in dictating this
threshold. As for downstream signaling,
is there a specific target of AKT that is
particularly dependent on the elevated
levels of AKT activity provided by
increased S473 phosphorylation and that
dictates the development of chemoresist-
ance? Although there are many candidate
pathways, previous studies on mouse
tumor models suggest that mTOR
complex 1 (mTORC1) activation can drive
chemoresistance in response to in-
creased AKT signaling (Wendel et al.,
2004). Finally, in addition to the mecha-SDH5 Mutations a
Somewhere Warb
William G. Kaelin, Jr.1,*
1Howard Hughes Medical Institute, Dana-Farb
MA 02115, USA
*Correspondence: william_kaelin@dfci.harvard
DOI 10.1016/j.ccr.2009.08.013
Paragangliomas have been linked to
issue of Science, Rutter and cowork
necessary for SDH assembly and
with familial paraganglioma.
Otto Warburg observed decades ago that
cancer cells display high rates of glycol-
ysis, with the subsequent conversion of
pyruvate to lactate, even when oxygen is
available for the far more efficient pro-
duction of ATP via the conversion of pyru-
vate to acetyl-CoA and subsequent ox-
idation via the Krebs cycle. How cancer
cells establish this pattern of ‘‘aerobic
glycolysis’’ is becoming clearer. For ex-
ample, many oncogenic mutations acti-
vate mTOR, which in turn induces HIF1a.
HIF1a transcriptionally activates many
genes that promote glucose uptake and
glycolysis. HIF1a also induces PDK1,
which phosphorylates pyruvate dehydro-
genase and thereby inhibits the entry of
pyruvate into the Krebs cycle (Kroemer
180 Cancer Cell 16, September 8, 2009 ª20nistic questions above, it will be important
to determine whether FKBP51 levels
provide a clinical biomarker predicting
whether a given tumor should be targeted
with chemotherapeutics alone or in
combination with emerging inhibitors of
the PI3K-AKT pathway.
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